(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hydrobromide | 121368-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;hydrobromide
• CAS: 121368-57-8
• 化学式: C19H21BrFNO3
• 分子量: 410.3
• InChiKey: NEFIGJLRLGOCSQ-RVXRQPKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  39.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Piperidine derivative for treating pain
  申请人：NOVO NORDISK A/S

  公开号：EP0269303B1

  公开（公告）日：1993-08-04
• Use of paroxetine for the manufacture of a medicament for the treatment of obesity
  申请人：NOVO NORDISK A/S

  公开号：EP0188081B1

  公开（公告）日：1992-03-11
• USE OF PAROXETINE FOR THE TREATMENT OF SENILE DEMENTIA, BULIMIA, MIGRAINE OR ANOREXIA
  申请人：BEECHAM GROUP plc

  公开号：EP0558679A1

  公开（公告）日：1993-09-08
• PAROXETINE SALTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1102764A1

  公开（公告）日：2001-05-30
• FORMULATION AND METHOD FOR THE RELEASE OF PAROXETINE IN THE LARGE INTESTINE
  申请人：Neely Jason

  公开号：US20090169616A1

  公开（公告）日：2009-07-02

  The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the active ingredient (e.g., paroxetine) in the large intestine of an individual in need thereof. In one embodiment, the present invention provides a controlled release paroxetine composition comprising paroxetine or a pharmaceutically acceptable salt thereof, in a controlled release swallow pharmaceutical formulation, that upon administration, releases the paroxetine substantially in the large intestine. For example, the controlled release paroxetine formulation may be formulated to release greater than about 50% of the paroxetine in the large intestine.